Impact of competition on reimbursement decisions for cancer drugs in China: an observational study.

ABSTRACT:

Background

Annual Chinese National negotiations for including innovative drugs in the National Reimbursement Drug List (NRDL) reveal an increasing number of new drugs with overlapping action mechanisms of action and similar indications. Yet, it is unclear if competition affects reimbursement decisions. Thus, we explored the impact of competition on reimbursement decisions for cancer drugs in China.

Methods

We identified the cancer drugs involved in NRDL negotiations from 2017 to 2022 and focused on the initial reimbursement decision for eligible newly negotiated drugs. Drugs were classified as within-class competitors based on their equivalent biological mechanisms of action and approved indications, including identified and potential competitors. Other variables included dr

SUBMITTER: Guan H 

PROVIDER: S-EPMC11326914 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature